Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Platinum 3Magnetic Resonance Spectroscopy 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Immunoglobulin G 2Disulfides 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2pembrolizumab 1durvalumab 1atezolizumab 1Radiotherapy, Image-Guided 1Radiation 1Pilocarpine 1Nivolumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Oropharyngeal Neoplasms × durvalumab × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡